Obesity Drugs: Stocks to Watch
George Budwell, The Motley Fool - Motley Fool - Tue Jun 09, 10:06AM CDT
Obesity is a big healthcare problem. In the U.S. alone, an estimated 35% of adults, or 85 million people, are believed to be obese, putting them at increased risk of certain forms of cancer, cardiovascular disease, and type 2 diabetes, among many...
OREX: 0.43 (unch), ARNA: 1.61 (+0.01)
Orexigen Therapeutics, Inc. Goes From Biotech Beauty to Dreadful Drugmaker
Brian Orelli, The Motley Fool - Motley Fool - Sat May 16, 10:04AM CDT
Orexigen Therapeutics has been the darling of the obesity drugmakers, doing something Arena Pharmaceuticals and VIVUS weren't able to do: keep its share price above where it was when its weight-loss drug was approved in September. ...
OREX: 0.43 (unch), VVUS: 1.14 (-0.03), ARNA: 1.61 (+0.01)
Why ImmunoGen Inc. is Soaring Higher Today
Todd Campbell, The Motley Fool - Motley Fool - Mon Mar 23, 2:25PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. ImmunoGen, What's happening: Shares in ...
IMGN: 3.13 (+0.02), AMGN: 156.05 (+1.78), LLY: 80.02 (+0.38)